J Korean Med Sci.  2010 Jan;25(1):117-122. 10.3346/jkms.2010.25.1.117.

Efficacy and Safety of Tamsulosin for the Treatment of Non-neurogenic Voiding Dysfunction in Females: A 8-Week Prospective Study

• Lee KS
• Han DH
• Lee YS
• Choo MS
• Yoo TK
• Park HJ
• Yoon H
• Jeong H
• Lee SJ
• Kim H
• Park WH

• KMID: 1713841
• DOI: http://doi.org/10.3346/jkms.2010.25.1.117

Abstract

We evaluated the therapeutic effects of tamsulosin for women with non-neurogenic voiding dysfunction. Women who had voiding dysfunctions for at least 3 months were included. Inclusion criteria were age > or =18 yr, International Prostate Symptom Score (IPSS) of > or =15, and maximum flow rate (Q(max)) of > or =12 mL/sec and/or postvoid residuals (PVR) of > or =150 mL. Patients with neurogenic voiding dysfunction or anatomical bladder outlet obstruction were excluded. All patients were classified according to the Blaivas-Groutz nomogram as having no or mild obstruction (group A) or moderate or severe obstruction (group B). After 8 weeks of treatment, treatment outcomes and adverse effects were evaluated. One hundred and six patients were evaluable (70 in group A, 36 in group B). After treatments, mean IPSS, bother scores, Q(max), PVR, diurnal and nocturnal micturition frequencies and scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire (BFLUTS-SF) were changed significantly. Eighty-nine patients (84%) reported that the treatment was beneficial. The proportion of patients reported that their bladder symptoms caused "moderate to many severe problems" were significantly decreased. No significant difference were observed between the groups in terms of IPSS, bother score, Q(max), PVR, micturition frequency, and BFLUTS-SF changes. Adverse effects related to medication were dizziness (n=3), de novo stress urinary incontinence (SUI) (n=3), aggravation of underlying SUI (n=1), fatigue (n=1). Tamsulosin was found to be effective in female patients with voiding dysfunction regardless of obstruction grade.

Keyword

Urination Disorders; Female; Adrenergic alpha-Antagonists; Outcomes Assessment

MeSH Terms

Adrenergic alpha-Antagonists/adverse effects/pharmacokinetics/*therapeutic use
Adult
Aged
Aged, 80 and over
Female
Humans
Middle Aged
Questionnaires
Severity of Illness Index
Sulfonamides/adverse effects/pharmacokinetics/*therapeutic use
Treatment Outcome
Urination Disorders/*drug therapy
Adrenergic alpha-Antagonists
Sulfonamides

Figure

• 

  Fig. 1 Classification of the study subjects using a bladder outlet obstruction nomogram as devised by Blaivas and Groutz; Group A-no obstruction or mild obstruction, Group B-moderate obstruction or severe obstruction. Pdetmax, maximum detrusor pressure; FreeQmax, maximum flow rate without catheter insertion.

• 

  Fig. 2 Comparisons of changes in clinical parameters-IPSS (A), Qmax, PVR (B), micturition frequency, FBC (C), BFLUTS-SF (D)-pre- vs. post-treatment. Values are adjusted using baseline values as covariates. White bars represent group A and black bars group B. P, group comparisons of improvement rates after treatment. IPSS, International Prostate Symptom Score; Qmax, maximum flow rate; PVR, postvoid residual; FBC, functional bladder capacity; QoL, quality of life.

• 

  Fig. 3 Proportion of patients by the patient's perception of bladder condition-pre- vs. post-treatment. White bars include no problems at all, some very minor problems, and some minor problems. Black bars include (some) moderate problems, severe problems, and many severe problems.

• 

  Fig. 4 Proportion of patients by the patient's perception of treatment benefit-pre- vs. post-treatment.

Reference

1. Groutz A, Blaivas JG. Non-neurogenic female voiding dysfunction. Curr Opin Urol. 2002. 12:311–316.

2. Kessler TM, Studer UE, Burkhard FC. The effect of terazosin on functional bladder outlet obstruction in women: a pilot study. J Urol. 2006. 176:1487–1492.

3. Pischedda A, Pirozzi Farina F, Madonia M, Cimino S, Morgia G. Use of alpha1-blockers in female functional bladder neck obstruction. Urol Int. 2005. 74:256–261.

4. Yamanishi T, Yasuda K, Kamai T, Tsujii T, Sakakibara R, Uchiyama T, Yoshida K. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol. 2004. 11:88–96.

5. Andersson KE, Lepor H, Wyllie MG. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997. 30:202–215.

6. Morita T, Latifpour J, O'Hollaren B, Wheeler MA, Weiss RM. Sex differences in function and distribution of alpha 1- and alpha 2-adrenoceptors in rabbit urethra. Am J Physiol. 1987. 252:F1124–F1128.

7. Nasu K, Moriyama N, Fukasawa R, Tsujimoto G, Tanaka T, Yano J, Kawabe K. Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol. 1998. 123:1289–1293.

8. Yablonsky F, Riffaud JP, Lacolle JY, Dausse JP. Alpha 1- and alpha 2-adrenoceptors in the smooth muscle of male and female rabbit urethra. Eur J Pharmacol. 1986. 121:1–8.

9. Schafer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, Sterling AM, Zinner NR, van Kerrebroeck P. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn. 2002. 21:261–274.

10. Brookes ST, Donovan JL, Wright M, Jackson S, Abrams P. A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence. Am J Obstet Gynecol. 2004. 191:73–82.

11. Blaivas JG, Groutz A. Bladder outlet obstruction nomogram for women with lower urinary tract symptomatology. Neurourol Urodyn. 2000. 19:553–564.

12. Gerstenberg TC, Lykkegaard Nielsen M, Lindenberg J. Spastic striated external sphincter syndrome imitating recurrent urinary tract infection in females. Effect of long-term alpha-adrenergic blockade with phenoxybenzamine. Eur Urol. 1983. 9:87–92.

13. Kawabe K, Niijima T. Use of an alpha 1-blocker, YM-12617, in micturition difficulty. Urol Int. 1987. 42:280–284.

14. Yoshida O, Takeuchi H, Hida S, Tomoyoshi T, Arai Y, Okada K, Akino H, Isomatsu I, Okabe T, Fukuyama T, Komatsu Y, Fukuyama T, Takahashi Y, Nakamura KH, Sanada S, Ueda M, Inoue H, Matsuo M, Watanabe J, Hayashida H, Itokawa Y. Clinical efficacy and safety of long-term administration of YM617 for urinary obstruction of the lower urinary tract. Hinyokika Kiyo. 1991. 37:421–429.

15. Reitz A, Haferkamp A, Kyburz T, Knapp PA, Wefer B, Schurch B. The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women. Eur Urol. 2004. 46:235–240.

16. Kumar A, Mandhani A, Gogoi S, Srivastava A. Management of functional bladder neck obstruction in women: use of alpha-blockers and pediatric resectoscope for bladder neck incision. J Urol. 1999. 162:2061–2065.

17. Akikwala TV, Fleischman N, Nitti VW. Comparison of diagnostic criteria for female bladder outlet obstruction. J Urol. 2006. 176:2093–2097.

18. Low BY, Liong ML, Yuen KH, Chee C, Leong WS, Chong WL, Khan NA, Cheah PY, Liong KK. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. J Urol. 2008. 179:1461–1469.

19. Pummangura N, Kochakarn W. Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women. Asian J Surg. 2007. 30:131–137.

20. Chang SJ, Chiang IN, Yu HJ. The effectiveness of tamsulosin in treating women with voiding difficulty. Int J Urol. 2008. 15:981–985.